RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAs posted beforehand a proposed M&A acquisition valuation of US$9-10 Billion for ONCY, as a bolt-on acquistion, comfortably falls within Big Pharma's M&A "sweet spot" range of US$5-15 Billion AND this range should incentivize ONCY's BOD to achieve the best acquisition value for ONCY as they possibly can.